EvaluatePharma has an antidote to any starry-eyed thinking about new drug launches. According to EP Vantage's new state-of-the-industry report, many of last year's rollouts are already disappointments, at least compared with previous sales projections.
Vertex Pharmaceuticals ($VRTX) watched its once-high-flying hepatitis C drug go into a nosedive for the fourth quarter. Incivek sales plummeted by 51% to $222.8 million, as fewer new patients elected to start therapy.
As Big Pharma looks to tap the burgeoning drug market in China, companies are realizing they can't bulldoze in with U.S.-approved drugs and expect a red carpet. Instead, firms such as Vertex and AstraZeneca's MedImmune are looking to partner up with local expertise to speed their way to capitalization.
Scientists at the National Cancer Institute, part of the National Institutes of Health, have developed a new gene that interferes with the clearance of hepatitis C infection.
Hurricane Sandy hasn't just shut down stock markets and forced evacuations. The powerful storm is shutting down some pharma earnings announcements, too.
Vertex is jettisoning one as a dud while racing ahead with the second into a mid-stage study slated to begin in a matter of weeks.
Drugmakers ranked among the world's top employers in two rankings by Science and Universum.
While R&D failures, patent problems and buyout fights are dominating Big Pharma news in recent weeks, the first half of the year has seen some sales results for some drugs that are nothing short of amazing. It illustrates how high returns can be when drugs make a competitive leap.
Regulators gave their final blessing to Vertex Pharmaceuticals' cystic fibrosis treatment Kalydeco, Almirall's lung drug Eklira Genuair, and Eisai's Fycompa seizure drug. And they granted Novartis dispensation to market its cancer drug Afinitor for breast cancer.
The recommendation by the CDC that the 70 million U.S. baby boomers all be tested for hepatitis C is a big gift for the newest hep C treatments.